EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Detectable C-Peptide and Diabetic Ketoacidosis Risk in Type 1 Diabetes

Mohammad I Abuabat, Dalton Budhram, Priya Bapat, Abdulmohsen Bakhsh, Yucheng Zhang iD, Wajeeha Cheema, Natasha J Verhoeff, Doug Mumford, Andrej Orszag, Michael Fralick, Alanna Weisman, Leif Erik Lovblom und 1 weitere

Diabetes Care · 2026

DOI: 10.2337/dc26-0220 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Diabetes Care, 2026. Verfasst von Mohammad I Abuabat und 12 weiteren Autor:innen. Beteiligte Einrichtung: Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: C-Peptide, Diabetic Ketoacidosis, Diabetes Mellitus, Type 1. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE To investigate whether detectable C-peptide levels in type 1 diabetes is associated with a lower risk of diabetic ketoacidosis (DKA). RESEARCH DESIGN AND METHODS We analyzed the Diabetes Control and Complications Trial publicly available data repository for the association between detectable stimulated C-peptide (>0.2 nmol/mL, measured annually) and DKA incidence over an average 6.5-year follow-up. We used crude and adjusted Andersen-Gill models for recurrent DKA events with time-dependent covariates. RESULTS Of the 1,441 participants (53% male, median age 27 years), 129 (9%) experienced 180 DKA events. Of these events, 179 (99.44%) occurred after C-peptide was ≤0.2 nmol/L in the prior year and only 1 event occurred with C-peptide >0.2 nmol/L. C-peptide >0.2 nmol/L was associated with a DKA hazard ratio of 0.07 (95% CI 0.01–0.48; P = 0.007), consistent across adjusted models. CONCLUSIONS Endogenous insulin production was significantly associated with lower DKA risk, suggesting that treatments preserving insulin production could decrease long-term DKA risk.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

C-PeptideDiabetic KetoacidosisDiabetes Mellitus, Type 1IncidenceFollow-Up StudiesRisk FactorsInsulinRandomized Controlled Trials as TopicRetrospective StudiesHumansMaleFemaleAdultHypoglycemic Agents

Substanzen

C-PeptideInsulinHypoglycemic Agents

Autor:innen und Institutionen

  • Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.
  • Division of Endocrinology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
  • Internal Medicine and Critical Care Department, King Abdullah bin Abdulaziz University Hospital, Princess Norah University, Riyadh, Saudi Arabia.
  • Division of General Internal Medicine, Department of Medicine, University Health Network and Sinai Health, University of Toronto, Toronto, Ontario, Canada.
  • Kidney and Pancreas Health Centre, Organ Transplant Centre of Excellence, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.
  • Patient-partner (person with lived type 1 diabetes experience).

ORCID-Profile: Yucheng Zhang, Bruce A Perkins

Zitieren

APA

Abuabat, M. I., Budhram, D., Bapat, P., Bakhsh, A., Zhang, Y., Cheema, W., Verhoeff, N. J., Mumford, D., Orszag, A., Fralick, M., Weisman, A., Lovblom, L. E., & Perkins, B. A. (2026). Detectable C-Peptide and Diabetic Ketoacidosis Risk in Type 1 Diabetes. Diabetes Care. https://doi.org/10.2337/dc26-0220

Vancouver

Abuabat MI, Budhram D, Bapat P, Bakhsh A, Zhang Y, Cheema W, et al. Detectable C-Peptide and Diabetic Ketoacidosis Risk in Type 1 Diabetes. Diabetes Care. 2026. doi:10.2337/dc26-0220

BibTeX
@article{Abuabat2026,
  author = {Abuabat, Mohammad I and Budhram, Dalton and Bapat, Priya and Bakhsh, Abdulmohsen and Zhang, Yucheng and Cheema, Wajeeha and Verhoeff, Natasha J and Mumford, Doug and Orszag, Andrej and Fralick, Michael and Weisman, Alanna and Lovblom, Leif Erik and Perkins, Bruce A},
  title = {Detectable C-Peptide and Diabetic Ketoacidosis Risk in Type 1 Diabetes},
  journal = {Diabetes Care},
  year = {2026},
  doi = {10.2337/dc26-0220}
}
Kostenlos starten →